首页> 美国卫生研究院文献>BMC Cancer >Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

【2h】

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

机译：吉西他滨和奥沙利铂联合或不联合厄洛替尼用于晚期胆道癌的III期研究在6周时肿瘤缩小预示了良好的临床结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe aim of this study was to determine whether early tumor shrinkage (ETS) at 6 weeks after treatment correlates with progression-free survival (PFS) and overall survival (OS) in advanced biliary tract cancer (BTC) patients receiving gemcitabine plus oxaliplatin (GEMOX), with or without erlotinib.

机译：背景本研究的目的是确定接受吉西他滨联合奥沙利铂（GEMOX）治疗的晚期胆道癌（BTC）患者在治疗后6周的早期肿瘤缩小（ETS）是否与无进展生存期（PFS）和总体生存期（OS）相关联），无论是否使用厄洛替尼。

著录项

期刊名称 BMC Cancer
作者
Seung Tae Kim; Kee-Taek Jang; Su Jin Lee; Hye-Lim Jang; Jeeyun Lee; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Joon Oh Park;
展开▼
作者单位

展开▼
年(卷),期 2015(15),-1
年度 2015
页码 530
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Early tumor shrinkage Erlotinib KRAS Biliary tract cancer GEMOX;

机译：早期肿瘤缩小;厄洛替尼;KRAS;胆道癌;GEMOX;

相似文献

外文文献
中文文献
专利

1. Tumour shrinkage at 6?weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer [J] . Seung Tae Kim, Kee-Taek Jang, Su Jin Lee, BMC Cancer . 2015,第1期

机译：在吉西他滨和奥沙利铂联合或不联合厄洛替尼治疗晚期胆道癌的III期临床研究中，肿瘤萎缩6周可预示良好的临床结果
2. Tumour shrinkage at 6?weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer [J] . Seung Tae Kim, Kee-Taek Jang, Su Jin Lee, BMC Cancer . 2015,第1期

机译：在吉西他滨和奥沙利铂联合或不联合厄洛替尼治疗晚期胆道癌的III期临床研究中，肿瘤萎缩6周可预示良好的临床结果
3. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer [J] . Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, Translational Oncology . 2015,第1期

机译：吉西他滨和奥沙利铂联合或不联合厄洛替尼治疗晚期胆道癌的3期临床结果的分子亚组分析
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer [O] . Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, 2015

机译：吉西他滨和奥沙利铂联合或不联合厄洛替尼治疗晚期胆道癌的3期临床结果的分子亚组分析
7. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer [O] . 2015

机译：吉西他滨和奥沙利铂联合或不联合厄洛替尼用于晚期胆道癌的III期研究在6周时肿瘤缩小预示了良好的临床结果

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

摘要

著录项

相似文献

相关主题

期刊订阅